Laurus Labs receives licence from DRDO to manufacture Covid drug 2DG

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

Topics

Laurus Labs | DRDO


PTI  | 
New Delhi 

Union Defence Minister Rajnath Singh hands over to Health Minister Harsh Vardhan the newly launched anti-Covid drug 2DG, developed by DRDO, on Monday. Photo: PTI

Union Defence Minister Rajnath Singh hands over to Health Minister Harsh Vardhan the newly launched anti-Covid drug 2DG, developed by DRDO, on Monday. Photo: PTI

Drug firm Laurus Labs on Friday said it has received the licence from Defence Research and Development Organisation to manufacture and market COVID-19 treatment drug 2-Deoxy-D-Glucose (2DG).

2DG has been given emergency approval by the Drugs Controller General of India (DCGI) for use on COVID-19 patients in the country, Laurus Labs said in a regulatory filing.

Laurus Labs has already applied with the Central Drugs Standard Control Organisation (CDSCO) for emergency use authorization (EUA) for 2DG,” it added.

On June 28, pharma major Dr Reddy’s announced the commercial launch of 2DG at a maximum retail price of Rs 990 per sachet.

Shares of Laurus Labs were trading at Rs 674.20 per scrip on BSE, up 1.08 per cent from the previous close.

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Fri, July 02 2021. 15:01 IST